<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="401">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01745081</url>
  </required_header>
  <id_info>
    <org_study_id>Study on cerebral relaxation</org_study_id>
    <nct_id>NCT01745081</nct_id>
  </id_info>
  <brief_title>Comparison of 20% Mannitol and 3% Hypertonic Saline for Cerebral Relaxation During Elective Supratentorial Craniotomies</brief_title>
  <official_title>Comparison of the Efficacy Between 20% Mannitol and 3% Hypertonic Saline, Given as a Bolus at the Beginning of Elective Supratentorial Craniotomy for Tumor Resection, in Favoring Cerebral Relaxation Evaluated by a Sub-dural Intracranial Pressure Measurement.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mannitol 20% has long been used to treat elevated intracranial hypertension in trauma and
      intensive care settings. More recent data indicate that hypertonic saline may be as
      effective or more effective than mannitol for this purpose, with possible fewer side
      effects.

      This study compares both agents in favoring cerebral relaxation during elective
      supratentorial procedures for tumor resection.

      Study hypothesis: 3% hypertonic saline will provide better cerebral relaxation with fewer
      side effects than 20% mannitol.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sub-dural intracranial pressure</measure>
    <time_frame>In average 30-60 minutes after intervention, just before dura mater opening</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sub-dural measure of intracranial pressure to evaluate cerebral relaxation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective evaluation of cerebral relaxation</measure>
    <time_frame>In average 30-60 minutes after intervention, just after dura mater opening</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjective evaluation by the surgeon of cerebral relaxation on a 4 point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lactate</measure>
    <time_frame>In average 5-8 hours after intervention, upon arrival in the intensive care unit</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Serum lactate measurement to assess tissue perfusion during the procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Osmotherapy</condition>
  <condition>Intracranial Pressure</condition>
  <arm_group>
    <arm_group_label>Mannitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bolus mannitol 20% at skin incision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertonic saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypertonic saline 3% at skin incision</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20% mannitol bolus administration</intervention_name>
    <arm_group_label>Mannitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic saline 3% bolus administration</intervention_name>
    <arm_group_label>Hypertonic saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for elective supratentorial craniotomy for tumor resection

          -  Presumed preoperative diagnosis of : astrocytoma (any grade), meningioma (any
             sub-type) or cerebral metastasis (any primary neoplasm)

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Reintervention

          -  Glasgow coma scale &lt; 13

          -  Emergency surgery or American Association of Anesthesiologists physical status class
             4 or 5

          -  Prone or lateral positioning

          -  Hypo or hypernatremia (serum sodium below 135 or above 150 meq/L)

          -  Osmotherapy (either mannitol or hypertonic saline) given in the last 24 hours

          -  Congestive heart failure (LVEF &lt; 40% or restrictive diastolic dysfunction on
             echocardiography)

          -  Chronic renal failure (creatinine clearance &lt; 30 ml/min)

          -  Pregnancy

          -  Obesity (BMI &gt; 40)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stéphane Coutu, MD, FRCPC</last_name>
    <phone>8193461110</phone>
    <phone_ext>14950</phone_ext>
    <email>stephane.coutu@usherbrooke.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>18193461110</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 6, 2012</lastchanged_date>
  <firstreceived_date>December 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Stéphane Coutu</investigator_full_name>
    <investigator_title>Principal study investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
